These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26275136)

  • 1. Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics.
    Gadkar K; Pastuskovas CV; Le Couter JE; Elliott JM; Zhang J; Lee CV; Sanowar S; Fuh G; Kim HS; Lombana TN; Spiess C; Nakamura M; Hass P; Shatz W; Meng YG; Scheer JM
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5390-400. PubMed ID: 26275136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in The Mouse Eye Following Intravitreal Administration.
    Bussing D; Li Y; Guo L; Verma A; Sullivan JM; Shah DK
    J Pharm Sci; 2023 Aug; 112(8):2276-2284. PubMed ID: 37062415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
    Bussing D; K Shah D
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Gadkar K; Mazer NA
    Mol Pharm; 2017 Aug; 14(8):2690-2696. PubMed ID: 28631484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
    Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab.
    Shatz W; Hass PE; Mathieu M; Kim HS; Leach K; Zhou M; Crawford Y; Shen A; Wang K; Chang DP; Maia M; Crowell SR; Dickmann L; Scheer JM; Kelley RF
    Mol Pharm; 2016 Sep; 13(9):2996-3003. PubMed ID: 27244474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye.
    Shatz W; Hass PE; Peer N; Paluch MT; Blanchette C; Han G; Sandoval W; Morando A; Loyet KM; Bantseev V; Booler H; Crowell S; Kamath A; Scheer JM; Kelley RF
    PLoS One; 2019; 14(6):e0218613. PubMed ID: 31251757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.